Liver perfusion with dynamic multidetector-row computed tomography as an objective method to evaluate the efficacy of chemotherapy in patients with colorectal cancer

Clinical Imaging

Volumn 33, Issue 4, 2009, Pages 289-294

  Pauls, Sandra ^a   Gabelmann, Andreas ^b   Heinz, Wolfgang ^c   Fröhlich, Eckhart ^c   Juchems, Markus Sebastian ^a   Brambs, Hans Jürgen ^a   Schmidt, Stefan Andreas ^c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Diagnostic Imaging Center Dreilaendereck   (Germany)

^c OLGAHOSPITAL   (Germany)

Author keywords

Chemotherapy; Computed tomography; Dynamic CT; Liver metastases; Liver perfusion

Indexed keywords

COLORECTAL CANCER; COMPUTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DYNAMIC CT; LIVER METASTASES; LIVER METASTASIS; LIVER PERFUSION; LOCAL ACTIVITY; MULTIDETECTOR ROW COMPUTED TOMOGRAPHY; OBJECTIVE METHODS; TUMOR MARKERS;

CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; PATHOLOGY; TUMORS;

LIVER;

CARCINOEMBRYONIC ANTIGEN; CONTRAST MEDIUM; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LAPAROTOMY; LIVER BIOPSY; LIVER METASTASIS; LIVER NECROSIS; LIVER PERFUSION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION IMAGING; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67649083526     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2008.10.030     Document Type: Article

References (25)

1. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J Clin 49 (1999) 33-64
2. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., Jemal A., Ward E., Anderson R.N., and Edwards B.K. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276-1299
3. Leichman L. The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer. Surg Oncol Clin N Am 16 (2007) 537-556
4. Mandalà M., Mosconi S., Quadri A., Milesi L., and Labianca R. Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. Expert Rev Anticancer Ther 7 (2007) 887-897
5. Lise M., Pilati P., Da Pian P., Mocellin S., Nitti D., and Corazzino S. Treatment options for liver metastases from colorectal cancer. J Exp Clin Cancer Res 22 4 Suppl (2003) 149-156
6. Duffy M.J., van Dalen A., Haglund C., Hansson L., Holinski-Feder E., Klapdor R., Lamerz R., Peltomaki P., Sturgeon C., and Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43 (2007) 1348-1360
7. Beziat C., Pilleul F., Yzebe D., Lombard-Bohas C., Mercier C., and Valette P.J. Detection of liver metastases in colorectal cancer on chemotherapy. Comparative study between MRI with teslascan and computed tomography with intravenous contrast media. J Radiol 85 (2004) 307-311
8. Schima W., Kulinna C., Langenberger H., and Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR?. Cancer Imaging 23 (2005) S149-S156
9. Ong K.O., and Leen E. Radiological staging of colorectal liver metastases. Surg Oncol 16 (2007) 7-14
10. Albrecht T., Hohmann J., Oldenburg A., Skrok J., and Wolf K.J. Detection and characterisation of liver metastases. Eur Radiol 14 Suppl 8 (2004) P25-P33
11. Hohmann J., Albrecht T., Hoffmann C.W., and Wolf K.J. Ultrasonographic detection of focal liver lesions: increased sensitivity and specificity with microbubble contrast agents. Eur J Radiol 46 (2003) 147-159
12. Hohmann J., Albrecht T., Oldenburg A., Skrok J., and Wolf K.J. Liver metastases in cancer: detection with contrast-enhanced ultrasonography. Abdom Imaging 29 (2004) 669-681
13. Arlt G., and Fuhrmann E. Ultrasound during follow-up of carcinoma. Chirurg 78 (2007) 449-453
14. Dietrich C.F., Kratzer W., Strobe D., Danse E., Fessl R., Bunk A., Vossas U., Hauenstein K., Koch W., Blank W., Oudkerk M., Hahn D., and Greis C. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 12 (2006) 1699-1705
15. Hosch W.P., Schmidt S.M., Plaza S., Dechow C., Schmidt J., Ley S., Kauffmann G.W., and Hansmann J. Comparison of CT during arterial portography and MR during arterial portography in the detection of liver metastases. AJR Am J Roentgenol 186 (2006) 1502-1511
16. Sahani D.V., Holalkere N.S., Mueller P.R., and Zhu A.X. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 243 (2007) 736-743
17. Pandharipande P.V., Krinsky G.A., Rusinek H., and Lee V.S. Perfusion imaging of the liver: current challenges and future goals. Radiology 234 (2005) 661-673
18. Zacharia T.T., Saini S., Halpern E.F., and Sumner J.E. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. AJR Am J Roentgenol 186 (2006) 1067-1070
19. Miller F.H., Butier R.S., Hoff F.L., Fitzgerald S.W., Nemcek A.A., and Gore R.M. Using triphasic helical CT to detect focal hepatic lesions in patients with neoplasms. AJR Am J Roentgenol 171 (1998) 643-649
20. Portugaller H.R., Stacher R., Komaz G., Aschauer M., Hausegger K.A., and Szolar D.H. The value of different spiral CT phases in the detection of liver metastases. Fortschr Roentgenstr 174 (2002) 452-458
21. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M.A., Mross K., Ball H.A., Lee L., Mietlowski W., Fuxuis S., Unger C., O'Byrne K., Henry A., Cherryman G.R., Laurent D., Dugan M., Marme D., and Steward W.P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 (2003) 3955-3964
22. van Laarhoven H.W., Klomp D.W., Rijpkema M., Kamm Y.L., Wagener D.J., Barentsz J.O., Punt C.J., and Heerschap A. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 20 (2007) 128-140
23. Dimitrakopoulou-Strauss A., Strauss L.G., and Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 47 (2003) 8-13
24. Bauer B., and Veit R. Dose rates in diagnostic radiology. Dtsch Arztebl 100 (2003) 2087-2088
25. Galanski M., Nagel H.D., and Stamm G. CT radiation exposure risk in Germany. Fortschr Roentgenstr 173 (2001) R1-R66